Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
30
IMNN Quote, Financials, Valuation and Earnings
Last price:
$0.60
Seasonality move
:
-1.23%
Day range:
$0.48 - $0.55
52-week range:
$0.37 - $3.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.05x
P/B ratio:
15.96x
Volume:
1.6M
Avg. volume:
2.4M
1-year change:
-65.01%
Market cap:
$7.2M
Revenue:
--
EPS (TTM):
-$1.36
Analysts' Opinion
-
Consensus RatingImunon has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.25, Imunon has an estimated upside of 1977.84% from its current price of $0.49.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $0.49.
Fair Value
-
According to the consensus of 3 analysts, Imunon has 1977.84% upside to fair value with a price target of $10.25 per share.
IMNN vs. S&P 500
-
Over the past 5 trading days, Imunon has underperformed the S&P 500 by -30.57% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Imunon does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Imunon has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Imunon reported revenues of --.
Earnings Growth
-
Imunon has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Imunon reported earnings per share of -$0.28.
Enterprise value:
4.3M
EV / Invested capital:
--
Price / LTM sales:
13.05x
EV / EBIT:
--
EV / Revenue:
8.68x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.27x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$24.8M | -$20.4M | -$18.3M | -$5M | -$4.1M | |
| EBITDA | -$31.3M | -$19.5M | -$17.1M | -$4.8M | -$3.9M | |
| Diluted EPS | -$4.03 | -$2.02 | -$1.36 | -$0.52 | -$0.28 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $56.2M | $43.9M | $36.3M | $12.1M | $5.1M | |
| Total Assets | $73M | $64.3M | $42.1M | $14.3M | $6.9M | |
| Current Liabilities | $6.7M | $6.6M | $10.4M | $4.8M | $5.8M | |
| Total Liabilities | $18.1M | $18.1M | $15.5M | $5.8M | $6.4M | |
| Total Equity | $55M | $46.3M | $26.6M | $8.5M | $452K | |
| Total Debt | $5.1M | $5.9M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$19.1M | -$20.9M | -$15.8M | -$5.9M | -$2.8M | |
| Cash From Investing | -$8.1M | $13M | $7.2M | $2.4M | -$259.7K | |
| Cash From Financing | $9.2M | -$6.1M | $9.2M | -- | $105.7K | |
| Free Cash Flow | -$19.4M | -$21.3M | -$16.1M | -$5.9M | -$3.1M | |
IMNN
Sector
Market Cap
$7.2M
$34.4M
Price % of 52-Week High
13.52%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-65.01%
-37.36%
Beta (5-Year)
1.927
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.62
200-day SMA
Sell
Level
$0.94
Bollinger Bands (100)
Sell
Level
0.58 - 1.36
Chaikin Money Flow
Sell
Level
-2.2M
20-day SMA
Sell
Level
$0.77
Relative Strength Index (RSI14)
Sell
Level
32.60
ADX Line
Sell
Level
39.47
Williams %R
Buy
Level
-97.1238
50-day SMA
Sell
Level
$1.04
MACD (12, 26)
Buy
Level
0.15
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Sell
Level
-3.5M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
Stock Forecast FAQ
In the current month, IMNN has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The IMNN average analyst price target in the past 3 months is $10.25.
-
Where Will Imunon Stock Be In 1 Year?
According to analysts, the consensus estimate is that Imunon share price will rise to $10.25 per share over the next 12 months.
-
What Do Analysts Say About Imunon?
Analysts are divided on their view about Imunon share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Imunon is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Imunon's Price Target?
The price target for Imunon over the next 1-year time period is forecast to be $10.25 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is IMNN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Imunon is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IMNN?
You can purchase shares of Imunon via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Imunon shares.
-
What Is The Imunon Share Price Today?
Imunon was last trading at $0.60 per share. This represents the most recent stock quote for Imunon. Yesterday, Imunon closed at $0.49 per share.
-
How To Buy Imunon Stock Online?
In order to purchase Imunon stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
